AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Tiziana Life Sciences Ltd (NASDAQ:TLSA)
1.6 USD
+0.180 12.676%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.42 |
|---|---|
| Change | +0.180 12.676% |
| 52 W H/L (in USD) | 1.270/0.410 |
| EBITDA (in USD) | -17.977M |
| PE Ratio | -- |
| Volume | 875986 |
| Diluted Eps TTM | -0.19 |
| Total Assets (in USD) | 12.184M |
|---|---|
| Total Liabilities (in USD) | 6.648M |
| Revenue TTM (in USD) | -3.595M |
| Cash (in USD) | 1.183M |
| Market Cap (in USD) | 93.291 M |
| Revenue Per Share TTM | -0.018 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
14/15 Conduit Street, London, United Kingdom, W1S 2XJ
44 20 7495 2379
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA | Founder, Exec. Chairman & Interim CEO | 1972 |
| 2. | Dr. Andrea Brancale | Scientific Founder | NA |
| 3. | Mr. Richard Clarkson Ph.D. | Scientific Founder | NA |
| 4. | Mr. Andrew Westwell Ph.D. | Scientific Founder | NA |
| 5. | Ms. Keeren Shah | Chief Financial Officer | 1977 |
| 6. | Dr. Matthew W. Davis M.D., RPh | Chief Medical Officer & Acting Chief Scientific Officer | NA |
| 7. | Prof. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | 1957 |
| 8. | Prof. Roberto Pellicciari Ph.D. | Consultant | NA |
| 9. | Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman & Interim CEO | 1972 |
| 10. | Ms. Keeren Shah | Chief Financial Officer | 1976 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -15.397M | -26.657M | -30.073M | -10.287M | -9.458M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -16.208M | -23.417M | -27.731M | -9.579M | -7.607M |
| Selling General Administrative | 1.631M | 0.855M | 14.023M | 6.207M | 4.417M |
| Gross Profit | - | 0M | 0M | 0M | 0M |
| Reconciled Depreciation | 0.051M | 0.141M | 0.091M | 0.198M | 0.013M |
| Ebit | -14.586M | -27.374M | -29.742M | -10.193M | -9.447M |
| Ebitda | -15.339M | -26.34M | -32.168M | -9.933M | -9.432M |
| Depreciation And Amortization | -0.753M | 1.034M | -2.426M | 0.26M | 0.015M |
| Operating Income | -14.586M | -27.374M | -29.742M | -10.193M | -9.447M |
| Other Operating Expenses | 14.586M | 27.374M | 32.273M | 10.193M | 9.447M |
| Interest Expense | 0.007M | 0.176M | 0.339M | 0.094M | 0.011M |
| Tax Provision | 0M | -3.24M | -2.207M | -0.54M | -1.534M |
| Interest Income | 0M | 0M | 0.008M | 0.001M | 0.009M |
| Net Interest Income | -0.007M | -0.176M | -0.312M | -0.072M | -0.009M |
| Income Tax Expense | 0.811M | -3.24M | -2.343M | -0.708M | -1.851M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 14.586M | 27.374M | 32.273M | 10.193M | 9.447M |
| Cost Of Revenue | - | 0M | 0M | 0M | 0M |
| Total Other Income Expense Net | -0.811M | 0.717M | -0.331M | -0.094M | -0.009M |
| Net Income From Continuing Ops | -15.397M | -23.417M | -26.131M | -7.306M | -6.299M |
| Net Income Applicable To Common Shares | -15.397M | -23.417M | -26.131M | -9.323M | -7.934M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 12.184M | 26.477M | 48.826M | 70.548M | 2.371M |
| Intangible Assets | - | - | 0.13M | 0.097M | - |
| Other Current Assets | - | 6.16M | 6.493M | 0.002M | 1.305M |
| Total Liab | 6.648M | 6.906M | 7.546M | 8.255M | 7.851M |
| Total Stockholder Equity | 5.536M | 19.571M | 41.28M | 62.293M | -5.481M |
| Other Current Liab | 0.014M | 1.579M | 3.14M | 0.084M | 0.083M |
| Common Stock | 0.103M | 0.102M | 0.102M | 7.956M | 5.374M |
| Capital Stock | 0.103M | 0.102M | 0.102M | 7.956M | 5.374M |
| Retained Earnings | -133.676M | -116.263M | -108.063M | -84.922M | -56.572M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.12M | 0.434M |
| Cash | 1.183M | 18.122M | 42.186M | 65.711M | 0.201M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 6.539M | 6.663M | 7.546M | 7.966M | 7.312M |
| Current Deferred Revenue | 2.25M | - | - | 4.255M | 0.591M |
| Net Debt | -0.936M | -17.757M | -42.186M | -65.157M | 0.616M |
| Short Term Debt | 0.138M | 0.122M | - | 0.266M | 0.278M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.247M | 0.365M | - | 0.555M | 0.817M |
| Other Stockholder Equity | 22.048M | 20.163M | 30.09M | 177.534M | 45.716M |
| Property Plant Equipment | - | 0.389M | 0.017M | 0.36M | 0.439M |
| Total Current Assets | 7.337M | 24.282M | 48.679M | 70.057M | 1.5M |
| Long Term Investments | 4.554M | 1.806M | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 6.052M | 5.99M | 5.307M | 3.779M | 1.277M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -5.99M | -5.307M | 0.565M | - |
| Accounts Payable | 4.137M | 4.962M | 4.406M | 3.361M | 6.36M |
| Accumulated Other Comprehensive Income | 117.061M | 115.569M | 119.151M | -38.275M | -0.035M |
| Non Currrent Assets Other | - | - | 0.13M | 0.12M | 0.433M |
| Non Current Assets Total | 4.847M | 2.195M | 0.147M | 0.491M | 0.871M |
| Capital Lease Obligations | 0.247M | 0.365M | 0M | 0.555M | 0.623M |
| Long Term Debt Total | - | - | - | - | 0.411M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -3.996M | 0.13M | -0.123M | -0.003M | 0M |
| Total Cashflows From Investing Activities | -2.676M | 0.13M | -0.123M | -0.004M | -0.004M |
| Total Cash From Financing Activities | -0.055M | -0.023M | 78.308M | 1.725M | 9.555M |
| Net Income | -15.397M | -26.657M | -30.073M | -10.287M | -9.458M |
| Change In Cash | -24.064M | -23.638M | 65.503M | -5.26M | 5.224M |
| Begin Period Cash Flow | 42.186M | 65.824M | 0.209M | 5.461M | 0.061M |
| End Period Cash Flow | 18.122M | 42.186M | 65.711M | 0.201M | 5.285M |
| Total Cash From Operating Activities | -19.615M | -21.762M | -12.67M | -6.982M | -4.331M |
| Depreciation | 0.051M | 0.141M | 0.097M | 0.26M | 0.015M |
| Other Cashflows From Investing Activities | - | 0.152M | 0.152M | 0.152M | 0.152M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | - | - | - | 1.473M | 8.569M |
| Other Cashflows From Financing Activities | -3.996M | 0.129M | 0.536M | -0.206M | -1.318M |
| Capital Expenditures | 0M | 0.022M | 0.135M | 0.004M | 0.004M |
| Change In Working Capital | -1.164M | -0.773M | -0.312M | 0.295M | 1.849M |
| Other Non Cash Items | -1.695M | 0.866M | 14.773M | 0.159M | 0.084M |
| Free Cash Flow | -19.615M | -21.784M | -12.805M | -6.986M | -4.331M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Nasdaq Composite ETF | 1 year ago | 160781 |
| 2. | Fidelity Nasdaq Composite Index | 1 year ago | 55884 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Geode Capital Management, LLC | 1 year ago | 211167 |
| 2. | HSBC Holdings PLC | 1 year ago | 164226 |
| 3. | Morgan Stanley - Brokerage Accounts | 1 year ago | 124131 |
| 4. | Ausdal Financial Partners Inc | 1 year ago | 55700 |
| 5. | Zhang Financial LLC | 1 year ago | 52060 |
| 6. | EWA, LLC | 1 year ago | 43476 |
| 7. | UBS Group AG | 1 year ago | 28559 |
| 8. | Bank of America Corp | 1 year ago | 27011 |
| 9. | Barclays PLC | 1 year ago | 17500 |
| 10. | Cubist Systematic Strategies, LLC | 1 year ago | 12099 |
| 11. | Jnba Financial Advisors Inc | 1 year ago | 12000 |
| 12. | TWO SIGMA SECURITIES, LLC | 1 year ago | 11349 |
| 13. | Crédit Agricole S.A. | 1 year ago | 10000 |
| 14. | TD Waterhouse Canada Inc | 1 year ago | 5000 |
| 15. | ARMSTRONG ADVISORY GROUP INC | 1 year ago | 3200 |
| 16. | NVWM, LLC | 1 year ago | 1444 |
| 17. | Cutler Group LP | 1 year ago | 1000 |
| 18. | Colonial Asset Management Inc | 1 year ago | 1000 |
| 19. | Northwestern Mutual Wealth Management Co | 1 year ago | 1000 |
| 20. | Tradewinds Capital Management, LLC | 1 year ago | 250 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...